Translational therapeutics in pleural malignancies

F. Rodriguez Panadero (Tomares (Sevilla), Spain)

Source: ERS Skills course - Medical thoracoscopy
Number: 13

Slide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Rodriguez Panadero (Tomares (Sevilla), Spain). Translational therapeutics in pleural malignancies. ERS Skills course - Medical thoracoscopy

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Rational approaches to pleural malignancies
Source: International Congress 2018 – State of the art session: Thoracic oncology
Year: 2018


Novel therapeutic strategies against malignant pleural mesothelioma by selumetinib-loaded targeted nanoparticles.
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017

Advances in pleural infection and malignancy
Source: Eur Respir Rev, 30 (159) 200002; 10.1183/16000617.0002-2020
Year: 2021



Multimodality therapy for malignant pleural mesothelioma
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004

Malignant mesothelioma: new treatment advances, including targeted therapies
Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care
Year: 2021


Biological markers of successful pleurodesis for malignant pleural effusion
Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside
Year: 2016


Multimodal management of malignant pleural mesothelioma: where are we today?
Source: Eur Respir J 2014; 44: 754-764
Year: 2014



Pleural effusion in lung cancer and targeted therapy
Source: Hands-on Course 2013 - Medical Thoracoscopy
Year: 2013

ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Source: Eur Respir J, 55 (6) 1900953; 10.1183/13993003.00953-2019
Year: 2020



Advances in pleural disease
Source: Eur Respir Rev 2016; 25: 108-109
Year: 2016


Immunotherapy for malignant pleural mesothelioma: ready for clinical practice?
Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies?
Year: 2016


Programme PD7 Designing and conducting research in malignant pleural effusion
Source: International Congress 2016 – PD7 Designing and conducting research in malignant pleural effusion
Year: 2016

Malignant pleural mesothelioma: new treatments, new hopes?
Source: Eur Respir J , 49 (3) 1700319; DOI: 10.1183/13993003.00319-2017
Year: 2017


The utility of survivin mRNA as a diagnostic biomarker in lung cancer with malignant pleural effusion
Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions
Year: 2013



Immunology-based therapeutic strategies in lung cancer and mesothelioma
Source: International Congress 2014 – Beyond tyrosine kinase inhibition: promising new developments in molecular oncology
Year: 2014



Role of tumor derived versican in experimental malignant pleural mesothelioma
Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside
Year: 2016

Detection of EpCAM-positive microparticles in pleural fluid: A new approach for the diagnosis of the tumoral origin of pleural effusions
Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management
Year: 2015



Update on biology and management of mesothelioma
Source: Eur Respir Rev, 30 (159) 200226; 10.1183/16000617.0226-2020
Year: 2021



Intrapleural photodynamic therapy for malignant pleural mesothelioma: A new dosimetry approach
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016


Management of malignant pleural effusion in recurrent SCLC by intrapleural gene therapy
Source: Eur Respir J 2003; 22: Suppl. 45, 61s
Year: 2003